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features: asthma, nasal polyposis, and respiratory reactions to cyclooxygenase-1 inhibitors (nonsteroidal
anti-inflammatory drugs). Electronic health records (EHRs) contain information on each feature of this
triad. OBJECTIVE We sought to determine whether an informatics algorithm applied to the EHR
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to search the EHRs of patients aged 18 years and older from the Partners Healthcare system over a
10-year period (2004-2014). Charts with search terms for asthma, nasal polyps, and record of respiratory
(cohort A) or unspecified (cohort B) reactions to nonsteroidal anti-inflammatory drugs were identified
as ”possible AERD.” Two clinical experts reviewed all charts to confirm a diagnosis of ”clinical AERD”
and classify cases as ”diagnosed AERD” or ”undiagnosed AERD” on the basis of physician-documented
AERD-specific terms in patient notes. RESULTS Our algorithm identified 731 ”possible AERD” cases,
of which 638 were not in our AERD patient registry. Chart review of cohorts A (n = 511) and B (n =
127) demonstrated a positive predictive value of 78.4% for ”clinical AERD,” which rose to 88.7% when
unspecified reactions were excluded. Of those with clinical AERD, 12.4% had no mention of AERD by
any treating caregiver and were classified as ”undiagnosed AERD.” ”Undiagnosed AERD” cases were
less likely than ”diagnosed AERD” cases to have been seen by an allergist/immunologist (38.7% vs
93.2%; P < .0001). CONCLUSIONS An informatics algorithm can successfully identify both known
and previously undiagnosed cases of AERD with a high positive predictive value. Involvement of an
allergist/immunologist significantly increases the likelihood of an AERD diagnosis.
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Abstract: 25 
Background: Aspirin-exacerbated respiratory disease (AERD) is characterized by three clinical 26 
features: asthma, nasal polyposis, and respiratory reactions to cyclooxygenase-1 inhibitors 27 
(NSAIDs). Electronic health records (EHRs) contain information on each feature of this triad.  28 
Objective: To determine if an informatics algorithm applied to the EHR could electronically 29 
identify patients with AERD. 30 
Methods: We developed an informatics algorithm to search the EHRs of patients age 18 and 31 
older from the Partners Healthcare system over a 10 year period (2004-2014). Charts with search 32 
terms for asthma, nasal polyps and record of respiratory (Cohort A) or unspecified (Cohort B) 33 
reactions to NSAIDs were identified as “possible AERD”. Two clinical experts reviewed all 34 
charts to confirm a diagnosis of “clinical AERD” and classify cases as “diagnosed AERD” or 35 
“undiagnosed AERD” based on physician documented AERD-specific terms in patient notes.  36 
Results: Our algorithm identified 731 “possible AERD” cases, of which 638 were not in our 37 
AERD patient registry. Chart review of cohorts A (n=511) and B (n=127) demonstrated a 38 
positive predictive value (PPV) of 78.4% for “clinical AERD”, which rose to 88.7% when 39 
unspecified reactions were excluded. Of those with clinical AERD, 12.4% had no mention of 40 
AERD by any treating caregiver and were classified as “undiagnosed AERD”. “Undiagnosed 41 
AERD” cases were less likely to have been seen by an allergist/immunologist than “diagnosed 42 
AERD” cases (38.7% vs. 93.2%, P<.0001). 43 
Conclusion: An informatics algorithm can successfully identify both known and previously 44 
undiagnosed cases of AERD with a high PPV. Involvement of an allergist/immunologist 45 
significantly increases the likelihood of an AERD diagnosis. 46 
  47 
Key Messages: 48 
 An informatics algorithm can be used to search electronic health records to identify 49 
diagnosed and previously undiagnosed cases of clinical aspirin-exacerbated respiratory 50 
disease (AERD). 51 
 Incomplete recording of drug reaction data by caregivers limits the PPV of this algorithm. 52 
 Involvement of allergy/immunology specialists in the care of subjects with asthma, nasal 53 
polyposis, and NSAID allergy increases the likelihood that a diagnosis of AERD will be 54 
made. 55 
 56 
Capsule Summary: 57 
An informatics search algorithm can successfully identify diagnosed and undiagnosed cases of 58 
aspirin-exacerbated respiratory disease (AERD) in the electronic health record. 59 
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Introduction: 83 
Electronic health records (EHR) provide the advantage of an electronically searchable 84 
patient chart and are now being widely used in North American and Europe. One of the ways 85 
EHRs can be used to improve patient care is to develop informatics algorithms for disease 86 
diagnosis.  Using this approach, cohorts of patients with disease-specific characteristics can be 87 
identified for diagnosis (1).  Identified patients may then benefit in a variety of ways, such as 88 
from disease-targeted therapeutics and from participation in clinical trials and translational 89 
research investigations. This may be particularly important in the field of clinical allergy and 90 
immunology where many of the common diseases encountered lack accurate disease-specific 91 
coding in our current systems.   92 
In the classic triad form, aspirin-exacerbated respiratory disease (AERD), also referred to 93 
as Samter’s Triad, is the unique clinical combination of chronic rhinosinusitis with nasal 94 
polyposis (CRSwNP), asthma,
 
and respiratory reactions to all inhibitors of cyclooxygenase 95 
(COX)-1. The syndrome affects 7.2% (95% CI, 5.26% to 9.03%) of adults with asthma and 96 
14.9% (95% CI, 6.48% to 23.29%) of those with severe asthma, and therefore may affect up to 2 97 
million U.S. adults (2).  Ingestion of aspirin or any COX-1 inhibitor elicits hypersensitivity 98 
reactions within 30 minutes to 3 hours that include worsening upper respiratory symptoms and 99 
acute bronchoconstriction, sometimes requiring emergency medical care. Although there are 100 
patients with respiratory reactions to COX-1 inhibitors who do not have all three components of 101 
this disease (3-5), we will consider the classic triad for the duration of this manuscript. AERD is 102 
a chronic medical condition that dramatically impacts quality of life and medical resource 103 
utilization beyond that of most aspirin-tolerant patients with asthma or CRSwNP (6). Despite the 104 
morbidity of the syndrome and its frequency in the adult asthmatic population, our clinical 105 
experience is that there is a delay of many months to years between the onset of AERD 106 
symptoms and a formal diagnosis (4), and research efforts in AERD are hampered by modest 107 
sample sizes.  108 
Unfortunately, AERD lacks a unifying ICD-9 or ICD-10 code. Since AERD is 109 
characterized by a unique triad, we hypothesized that the simultaneous use of ICD-9 codes for 110 
asthma and nasal polyps, problem list entries, and medication allergy entries would automatically 111 
identify a cohort of possible AERD cases. Therefore, we developed and tested an EHR algorithm 112 
to identify subjects with AERD. 113 
Methods: 114 
Informatics Algorithms 115 
Applying an informatics algorithm to the Partners Research Patient Data Repository 116 
(RPDR) (1, 7), the EHRs at 2 academic hospitals (Massachusetts General Hospital and Brigham 117 
and Women’s Hospital [BWH]) and one community hospital (Faulkner Hospital) affiliated with 118 
the Partners Healthcare system were searched over a 10 year period (12/2004-11/2014). IRB 119 
approval was obtained for this study. The EHR at the institutions searched is entirely electronic 120 
and included both inpatient and outpatient data from any affiliated hospital or clinic. All charts of 121 
patients age 18 or older who had one or more encounters during this time period were searched 122 
for AERD-relevant features. One RPDR query (Repository Table E1) was designed to find 123 
patients with ICD-9 codes, problem list entries, laboratory values (eosinophils >500/µL) or 124 
medications associated with asthma and with ICD-9 codes, problem list entries, intranasal 125 
steroids or surgical billing codes related to nasal polyposis. The second RPDR query was 126 
designed to find patients with NSAID allergy. The union of the two RPDR queries resulted in 127 
datasets including 168,126 patients, which were further processed as described below. 128 
The datasets obtained from RPDR were preprocessed, i.e. decrypted and decompressed, 129 
and aggregation algorithms were used to summarize the resulting raw data tables, enabling first 130 
reviews of the data. Because the RPDR queries were designed to capture all patients of potential 131 
interest, structured query language (SQL) statements were used to filter and analyze patient data 132 
and allow for the identification of the most important structured terms used in the final 133 
algorithm. 134 
Three preliminary SQL queries were developed for each characteristic of AERD, 135 
searching the data tables for specific terms, e.g. “asthma”, and misspellings such as 136 
“amaphylaxis” were also considered. Each query returned one patient population with asthma 137 
(Repository Figure E1), one population with nasal polyps (Repository Figure E2) and one 138 
population with NSAID allergy (Repository Figure E3). The NSAID allergy SQL was designed 139 
to identify charts that reported reactions typical of the respiratory symptoms triggered by 140 
NSAIDs in AERD or charts that reported unspecified (“unknown”) reactions to NSAIDs. 141 
Reaction types not classically associated with AERD, e.g. gastritis or urticaria, were excluded. 142 
The results (patient sets) of each query were used to further refine the SQL queries filtering more 143 
specific data about the identified populations. The BWH AERD patient registry (n=96), a well-144 
phenotyped database of patients with aspirin-challenge confirmed AERD, was also used to 145 
identify information of increased significance, and the SQL queries were iteratively revised 146 
several times. In the example of nasal polyps, if a problem was noted by a clinician that did not 147 
contain the necessary key words but one of the terms “sinus”, “nasal” or “allergic rhinitis”, then 148 
the problem-associated comment was searched for “polyp”.  149 
Over the course of these iterations, it became clear that diagnoses (ICD-9 codes), 150 
problems including associated comments, and allergens, focusing only on those with specified 151 
respiratory (e.g. bronchospasm, wheeze, nasal congestion) reactions, or unspecified reactions to 152 
any inhibitor of COX-1, were the most important components to identify potential AERD 153 
patients. The intersection of the three populations identified “possible AERD” cases (Figure 1), 154 
which were further stratified by the type of reaction to an NSAID recorded in the EMR; Cohort 155 
A included cases where specific respiratory symptoms were recorded and Cohort B included 156 
cases where the reaction symptoms were unspecified, i.e. recorded as “unknown”. 157 
A number of cases identified as “possible AERD” were already recorded as having 158 
known AERD within structured information in the EHR e.g. problem lists and allergies and/or 159 
through involvement in the BWH AERD patient registry. Therefore a fourth SQL query 160 
(Supplementary File E5) was set up that searched only for AERD-specific terms within 161 
structured information in the EHR, to determine if that more simplified approach would be 162 
sufficient to identify cases of AERD from the EHR.  163 
Chart Reviews 164 
Two allergy/immunology experts with a clinical focus on AERD independently 165 
performed chart reviews. All charts from Cohort A and Cohort B were reviewed by at least one 166 
reviewer, with 20 charts from each cohort reviewed by both reviewers to assess the inter-rater 167 
agreement (Kappa). Reviewers defined “clinical AERD” as the presence of an asthma diagnosis, 168 
nasal polyps and a report of a classical respiratory reaction to one or more NSAIDs. The 169 
presence of nasal polyposis was confirmed during chart review if one of the following criteria 170 
were met: 1) documentation of rhinoscopic evidence of nasal polyposis, 2) surigical/pathologic 171 
report confirming nasal polyposis, or 3) radiologic evidence of nasal polyposis. Cases which 172 
carried a diagnosis of cystic fibrosis, sinus malignancy, or unilateral sinus disease or were 173 
determined by chart review to either not meet criteria for a diagnosis of AERD or not have 174 
sufficient information recorded within their chart to determine the diagnosis, were labeled “Not 175 
AERD”. During this review, unstructured EHR data, including progress, hospital visit, and 176 
surgical procedure notes, were reviewed using a queriable patient inference dossier (8) to 177 
identify if a caregiver had made a prior diagnosis of AERD (or another term for the disease, 178 
including Samter’s triad, aspirin-sensitive asthma, aspirin-intolerant asthma, or triad asthma) that 179 
was not recorded in the structured data. These cases were defined as “diagnosed AERD.” Cases 180 
established by expert review as having “clinical AERD” but lacking any documentation of 181 
AERD in either the structured or unstructured data within the EHR were considered 182 
“undiagnosed AERD.” Whether the patient had ever had clinical involvement of pulmonary, 183 
allergy/immunology and otolaryngology specialists in each case was noted. 184 
Statistical Analyses 185 
 All data are represented as mean ± standard deviation (SD) unless otherwise noted. 186 
Cohen’s kappa coefficient was used to measure inter-rater agreement on the clinical diagnosis of 187 
AERD by our expert reviewers. Positive-predictive values (PPV) were calculated from chart 188 
reviews of Cohort A, B, and the BWH AERD registry. Fisher’s exact test was used to assess 189 
differences in gender and race between “diagnosed” and “undiagnosed” AERD; a Mann-190 
Whitney U test was employed to determine difference in age. Differences in rates of specialty 191 
physician evaluations were assessed using a contingency table and Fisher’s exact test. T tests 192 
were performed to determine differences in number of encounters. GraphPad Prism version 6.07 193 
for windows, GraphPad Software, La Jolla California USA, www.graphpad.com, SAS software, 194 
version 9.4, Cary, North Carolina, USA, and/or  R version 3.2.1, R Foundation for Statistical 195 
Computing, Vienna, Austria was used to complete these analyses. 196 
Results 197 
A total of 2,647,842 charts were queried using RPDR between 12/1/2004 and 198 
11/30/2014. The cohort defined by the intersection of the asthma (SQL #1), nasal polyp (SQL 199 
#2) and NSAID allergy (SQL #3) queries was considered to contain “possible AERD” cases 200 
(n=732, Figure 1). One case was identified as a test patient, a virtual patient generated for 201 
training purposes, and excluded and 93 cases participated in the AERD registry and had known 202 
confirmed AERD. Of the remaining 638 cases, Cohort A (n=511) included cases with record of a 203 
respiratory reaction to NSAIDs and Cohort B (n=127) included cases with an unspecified 204 
reaction to an NSAID (Figure 2).  205 
Cohorts A and B were independently reviewed by both reviewers. The inter-rater 206 
agreement value, kappa, for each cohort was 100%. The PPV for the identification of “clinical 207 
AERD” cases using this informatics algorithm is 81.1% (Cohorts A, B, and the BWH AERD 208 
Registry). The PPV excluding the AERD registry charts (Cohort A and B) is 78.4% which rises 209 
to 88.7% if only cases with a specified respiratory reaction to an NSAID (Cohort A) are 210 
considered. After expert review of progress notes, 12.4% of “clinical AERD” cases identified 211 
(11.9% in Cohort A and 17.0% in Cohort B) were labeled “undiagnosed AERD”, indicating that 212 
the expert review agreed they had the triad of clinical symptoms consistent with AERD but there 213 
was no mention of AERD or a similar term in the EHR (Figure 2). Significantly less involvement 214 
from allergy/immunology specialists was noted in the care of “undiagnosed AERD” cases as 215 
compared with “diagnosed AERD” cases (38.7% vs. 93.2%, P<..0001; Table I). Among those 216 
“clinical AERD” patients who had been evaluated by only one type of specialty provider, 100% 217 
of the 6 cases seen by only allergy, 40.9% of the 44 cases seen by only ENT, and 33.3% of the 3 218 
cases seen by only pulmonary were recorded in the EHR as having been diagnosed with AERD 219 
(P<.05). 220 
The patient demographics of “diagnosed” and “undiagnosed AERD” and the BWH 221 
AERD patient registry are reported in Table II. The diagnosed AERD cohort median age 222 
(interquartile range (IQR)) was slightly younger than the undiagnosed cohort (54 (IQR=45-65), 223 
58 (IQR=51-72), respectively, P<.01). There was no significant difference in sex or race between 224 
cohorts. The median number of patient encounters with the Partners Healthcare system was not 225 
different between those with “diagnosed” and “undiagnosed” AERD (37.5 (IQR=11-101) and 226 
54.5 (IQR=19-126), respectively, P=.31). 227 
Application of SQL #4 (n=255) identified only 28.9% (n=211) of the “possible AERD” 228 
cases (Figure 3) and an additional 44 cases not identified by the EHR algorithm. Of the 42 charts 229 
in SQL#4 not identified by the EHR algorithm or included in the BWH AERD registry, 20 230 
lacked one or more components of the triad and were considered “Not AERD” and 22 (52.4%) 231 
were labeled “clinical AERD” after expert chart review. Application of the primary EHR search 232 
algorithm to just the BWH AERD patient registry identified 93 of 96 patients (96.9%). Of the 3 233 
cases from the BWH AERD patient registry that were not identified by the AERD algorithm, 2 234 
had no NSAID allergy recorded, representing serious omissions that impact patient safety, and 235 
one lacked appropriate documentation of nasal polyps. Taken together, our primary algorithm 236 
failed to identify 3.7% [23 of 618 (Clinical AERD (n=500) + BWH AERD Registry (n=96) + 237 
SQL#4 Clinical AERD (n=22)] of the known patients with AERD in the EHR. 238 
Discussion 239 
We demonstrate that an informatics algorithmic approach can be used to identify both 240 
diagnosed and previously undiagnosed cases of AERD. Our approach identified 593 known or 241 
expert-confirmed cases of AERD with a PPV of 81.1% while missing only 3.7% of the known 242 
patients with AERD in the EHR. Among those cases identified by our algorithm and confirmed 243 
by expert review as having “clinical AERD”, 12.4% (n=62) carried no mention of AERD or an 244 
equivalent term in the medical chart. As far as could be determined from their medical chart, no 245 
caregiver had ever realized the connection between their clinical triad of symptoms and therefore 246 
these cases had never been given the diagnosis of AERD (Figure 2). Patients in this 247 
“undiagnosed AERD” category were less likely to have been evaluated by an 248 
allergy/immunology specialist (Table I), highlighting the role of allergist/immunologists in 249 
correctly identifying this disease. Cases of “undiagnosed AERD” identified by the algorithm 250 
have not yet been exposed to the gold standard for diagnosis of AERD, aspirin challenge, to 251 
confirm the assessment made by our expert clinicians. The current literature suggests up to 15% 252 
of those cases meeting clinical criteria for AERD may have a negative aspirin challenge (9, 10). 253 
However, the clinical experience from our institution involving more than 150 aspirin challenges 254 
is that <5% of patients with asthma, nasal polyposis and a historical respiratory reaction to an 255 
NSAID go on to have a negative aspirin challenge (4). This suggests our informatics algorithm 256 
can identify new diagnoses of AERD and could facilitate access to disease-specific treatments 257 
for these patients, which have been shown to improve their care (11-13).  258 
Algorithm-identified cases of AERD, both “diagnosed” and “undiagnosed”, demonstrate 259 
the classical female predominance (9, 10, 14). The slightly younger age in the “diagnosed 260 
AERD” cases cannot easily be explained with the data generated in this study (Table II). One 261 
hypothesis drawn from our clinical experience is that younger patients with AERD are using 262 
electronic resources to connect their triad of symptoms and may present to their providers 263 
questioning a diagnosis of AERD, leading to greater consideration and confirmation of AERD. 264 
Previously there has been no racial predilection for the development of AERD reported and our 265 
racial demographics reflect the racial distribution of the Partners Healthcare patient population. 266 
Race does not predict if a case is diagnosed or not. No data about asthma severity/control was 267 
collected/analyzed and no conclusions can be made about the nature of the upper or lower 268 
respiratory disease in the cohorts. The lack of a difference in number of encounters between the 269 
groups suggests both groups utilize the healthcare system at similar rates, had similar amounts of 270 
data available for chart review, and that the number of encounters with the healthcare system did 271 
not bias towards identifying an “undiagnosed” case of AERD.  272 
The benefit of using such an algorithm to identify patients with AERD is multi-factorial. 273 
In the short-term, patients with AERD would have better access to disease-specific therapy 274 
including zileuton which improves nasal symptoms and FEV1(15) and high-dose aspirin therapy 275 
which improves sinus and asthma symptom scores and decreases nasal congestion, corticosteroid 276 
use (oral and inhaled), the number of sinus infections per year, and the need for repeat 277 
polypectomy  (16, 17).  Additionally, of the cases of AERD we identified, less than 20% are 278 
participating in the BWH AERD patient registry. As patients who participate in the registry are 279 
provided with formal educational materials about their disease and are offered involvement in 280 
research opportunities, this highlights the potential to engage 500 new subjects in clinical or 281 
translational research focused on AERD at our or any other institution. Use of an informatics 282 
algorithm at any institution employing an electronic medical record to identify patients with 283 
AERD,  a disease lacking a unifying ICD-9 or 10 code or diagnostic laboratory test, has the 284 
power to improve patient care immediately and to support the research endeavors that will yield 285 
future advances in patient care. 286 
The algorithm we present used commonly-coded information for diagnosis, billing and 287 
allergy information that is captured in any electronic medical record. Our development of an 288 
EHR-based phenotyping algorithm for AERD can be deployed in other electronic medical record 289 
programs, both nationally and internationally, which are capturing data on the diagnosis of 290 
asthma, nasal polyps and allergy to NSAIDs (18). Similar algorithms for rheumatoid arthritis, 291 
drug-induced liver injury and genomic phenotyping have been successfully employed across 2-292 
13 different EHR platforms (19-21). The data model employed by our EHR does not differ 293 
substantially from other EHRs both nationally and internationally. Minor adjustments for 294 
language and regional differences in terminology (e.g. NERD, i.e. NSAID-exacerbated 295 
respiratory disease, which is commonly used in Europe) would be required to maximize the 296 
success of adapting this algorithm. Although we have generated this algorithm and searched the 297 
patient charts from two large referral-based tertiary care centers with active research programs in 298 
asthma, nasal polyps, and AERD, the data used to identify potential cases of AERD is basic 299 
information that should be captured by primary care and specialist providers even if they have no 300 
knowledge of AERD.  301 
As with all informatics algorithms, our algorithm is limited by the amount and the quality 302 
of the data contained within the EHR, specifically among the details of drug allergy recordings 303 
(22). The PPV of our algorithm drops from 88.7% (Cohort A) to 78.4% (Cohort A and B) if we 304 
include cases in which the symptoms of reaction to NSAIDs are not specified. Of those cases in 305 
Cohort A determined not to have AERD, 21 of 58 of them were classified as such because they 306 
lacked a sufficient NSAID allergy history in the chart to meet our pre-specified criteria for 307 
characterization as AERD. The inclusion of SQL#4 confirms that use of AERD-specific search 308 
terms alone vastly underestimates the potential cases of AERD in the EHR (Figure 3). A closer 309 
look at those 42 charts identified by SQL #4 which were not found by the primary EHR AERD 310 
algorithm or included in the BWH AERD registry highlights the danger of incomplete and 311 
inaccurate information contained within the EHR. 47.6% (n=20) of these charts were eventually 312 
classified as “Not AERD” due to one of two reasons: 1) AERD had initially been considered 313 
and/or recorded by a provider but then ruled out by a negative aspirin challenge or 2) the EHR 314 
did not have enough information to confirm a diagnosis of AERD. Because of these data quality 315 
limitations, use of any algorithm is likely to under-detect possible cases of AERD and no 316 
conclusions about the prevalence of AERD can be drawn from this study. In primary care 317 
settings, relying on a single ICD-9 or 10 code for the diagnosis of asthma lacks specificity (23). 318 
The requirement for multiple ICD-9/10 codes and/or additional data, e.g. concomitant 319 
prescriptions for disease-targeted therapy such as β-agonists, may be necessary to improve the 320 
specificity of this algorithm. However, no improvement in the algorithm methods can make up 321 
for the omission of information in the EHR. Our work underscores the need for complete and 322 
specific data entry in the EHR in order to maximize the patient safety and research potential. 323 
In our healthcare system with more than 2,000,000 patient records between 11/2004-324 
11/2014, given the known prevalence of asthma in US adults is 7% (24), and the prevalence of 325 
AERD is estimated at 7% of adults with asthma (2), we would have predicted to find >10,000 326 
cases of AERD. In addition to the data quality issues our algorithm identified, patients referred 327 
from an outside provider to a tertiary care center for specialty care may lack complete EHR data, 328 
specifically ICD-9 coding or problem list entries for asthma or nasal polyps, if those problems 329 
are not being addressed by the specialty provider. We focused our efforts on the identification of 330 
the classic triad of AERD (25), and did not focus on identifying those cases which lack either 331 
asthma or nasal polyposis but demonstrate the sterotypical respiratory reaction following the 332 
ingestion of a COX-1 inhibitor (3-5), likely missing these non-classic presentations of AERD. 333 
Additionally, our hospital system is known for oncology, rheumatology, and obstetric care and 334 
our starting population likely is over represented for these conditions which do not have any 335 
association with asthma.  336 
The patient population searched presents two unique characteristics about the charts 337 
queried. First, the tertiary care setting may result in incomplete health records, as discussed 338 
above, and bias the algorithm and the chart review against assigning a diagnosis of AERD. 339 
Given the lack of disease-unique therapeutics or laboratory values in AERD, no other recorded 340 
data points can be depended upon to adequately replace missing diagnoses. Second, our cohort is 341 
likely to have more AERD-specific information available within the EHR, specifically in the 342 
problem list where an “aspirin-intolerant asthma with nasal polyposis” problem has been created 343 
at the request of BWH AERD Center physicians. We anticipate higher rates of “undiagnosed 344 
AERD” would be identified by application of this algorithm to another setting that does not have 345 
an active AERD clinical and research program. The algorithm we present does not require an 346 
AERD-specific term, which SQL#4 demonstrated was neither sensitive nor specific for AERD, 347 
and application of this algorithm approach to another EHR should have no impact on the 348 
clinically significant identification of cases which fall into Cohorts A and B.  349 
New strategies employing the EHR to increase identification of patients with AERD and 350 
other allergic diseases hold great promise for improving clinical care and expanding access to 351 
specialists in the field. A recent survey of subjects with AERD highlighted the disconnect 352 
between beneficial therapies and their use in patients with AERD.  91% of AERD subjects 353 
reported aspirin therapy was beneficial but <50% of the survey population had been offered 354 
aspirin therapy (6). The present algorithmic approach could be used to display automatic alert 355 
notifications to physicians in order to promote the consideration of AERD and improve 356 
documentation of AERD (26), while offering evidence-based information and detailed advice 357 
including referral options (27). Providing patients with an accurate diagnosis may empower them 358 
to seek out effective treatments for their disease and/or engage in clinical trials that have the 359 
potential to transform the future of AERD-specific care. The high PPV of our algorithm would 360 
likely generate notifications at low risk for inducing alert fatigue (28). In addition, this algorithm 361 
could be used to prioritize the generation of medication alerts for NSAID prescriptions in those 362 
patients who have a record of NSAID allergy in conjunction with a history of asthma and/or 363 
nasal polyps (29). Future work assessing the gains in patient care and safety from such an 364 
approach is needed. 365 
AERD is an under-recognized but important disease in which current technology can be 366 
employed to better serve the needs of our patients. Leveraging the power of the EHR to identify 367 
new diagnoses has the potential to shorten the length of time between symptom onset and 368 
diagnosis and to positively affect care for patients with AERD.  369 
 370 
 371 
  372 
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  456 
Table I. Allergist/immunologist involvement in undiagnosed and diagnosed clinical AERD. 457 
The charts of undiagnosed (n= 62) and diagnosed AERD (n= 438) cases were assessed for 458 
involvement by allergy/immunology specialists. 459 
 460 
 461 
 462 
 463 
 464 
Table II. Demographics of diagnosed and undiagnosed AERD cases and the Brigham and 465 
Women’s Hospital AERD registry. Statistical analyses run between diagnosed and 466 
undiagnosed AERD. The BWH AERD registry demographics have been included for reference. 467 
n – sample size; IQR – interquartile range; # - Fisher’s exact test; ^ - Mann-Whitney U test; * - T 468 
test. 469 
  
Diagnosed 
AERD 
Undiagnosed 
AERD p-value 
 
AERD 
Registry 
Sample size, n 438 62 
  
96 
Male, n (%)
#
  179 (40.9) 26 (41.9) 0.9 
 
42 (43.8) 
Median age, years 
(IQR)^ 54 (45-65) 58 (51-72) <.01 
 
52 
(42-
60) 
Race, n (%)
#
  
    
0.7 
      White/Caucasian 356 (81.3) 53 (85.5) 
  
87 (90.6) 
   Black/African 
American 27 (6.2) 2 (3.2) 
  
3 (3.1) 
   Hispanic/Latino 16 (3.7) 3 (4.8) 
  
2 (2.1) 
   Asian 5 (1.1) 1 (1.6) 
  
3 (3.1) 
   Other/Unknown 34 (7.8) 3 (4.8) 
  
1 (1.0) 
Encounters, total, 
median (IQR)* 
37.5 (11-101) 54.5 (19-126) 0.3 
   
  AERD   
  Diagnosed Undiagnosed Total 
Allergist/immunologist Involvement 408 24   
No Allergist/immunologist Involvement 30 38   
Total, n 438 62 500 
Allergy Involvement % 93.2 38.7   
Figure 1. Venn diagram of the clinical characteristics of cases identified by an AERD 470 
bioinformatics algorithm. From 2,647,842 patients seen within the Partners Healthcare system 471 
between 12/2004 and 11/2014 aged 18 and older, we identified cases with a diagnosis of asthma, 472 
nasal polyps, and/or NSAID allergy. NSAID allergy was restricted to only those with a specified 473 
respiratory reaction to NSAIDs or an unspecified (“unknown”) reaction. The cohort of “possible 474 
AERD” cases, in yellow, lies at the intersection of all three clinical characteristics. n – sample 475 
size. 476 
Figure 2. Flow chart for the assessment of the possible AERD cohort. PPV for identifying 477 
AERD in subjects with asthma, nasal polyposis and a recorded respiratory reaction to an NSAID 478 
(Cohorts A) = 88.7%. PPV for identifying AERD subjects having a recorded respiratory or 479 
unspecified reaction to an NSAID (Cohort A+B) not previously enrolled in the AERD registry = 480 
78.4%. PPV for algorithm identifying all patients with AERD (Cohort A+B+AERD registry) = 481 
81.1%. n – sample size. * - 732 charts were initially identified by the algorithm and one test chart 482 
was excluded. 483 
Figure 3. Venn diagram of the possible AERD cases identified by the AERD algorithm 484 
(SQL#1-3), AERD specific search terms (SQL#4), and the BWH AERD Registry. 485 
 486 
Figure 1. Venn diagram of the clinical characteristics of cases identified by an AERD 
bioinformatics algorithm. 
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Figure 3. Venn diagram of the possible AERD cases identified by the AERD algorithm 
(SQL#1-3), AERD specific search terms (SQL#4), and the BWH AERD Registry. 
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Repository Legends: 1 
Repository Table E1. Partners Research Patient Data Repository (RPDR) queries used to 2 
identify charts containing information supporting a diagnosis of asthma/nasal polyps and 3 
aspirin/non-steroidal anti-inflammatory drug (NSAID) allergy. 4 
Repository Figure E1. Structured query language (SQL) query #1 developed to identify a 5 
patient population with asthma. 6 
Repository Figure E2. Structured query language (SQL) query #2 developed to identify a 7 
patient population with nasal polyps. 8 
Repository Figure E3. Structured query language (SQL) query #3 developed to identify a 9 
patient population with non-steroidal anti-inflammatory drug (NSAID) hypersensitivity reactions 10 
typical of the respiratory symptoms triggered by NSAIDs in aspirin-exacerbated respiratory 11 
disease (AERD) or charts that reported unspecified (“unknown”) reactions to NSAIDs . Asa – 12 
aspirin. Sob – shortness of breath.  13 
Repository Figure E4. Structured query language (SQL) query #4 developed to identify a 14 
patient population with known or suspected aspirin-exacerbated respiratory disease (AERD). Asa 15 
– aspirin. Sob – shortness of breath. 16 
 17 
Repository Table 1: 
 
Asthma/Nasal polyps RPDR query: 
 
Wheezing 786.07-.09       OR 
Asthma, all types and exacerbation states – 493.0-99   OR 
Diagnosis-Related Groups for bronchitis and asthma age >17  OR 
Prescription, inpatient or outpatient, in all forms: 
Albuterol– inhaler and nebulizer  OR 
Ipratropium plus albuterol   OR 
Levalbuterol    OR 
Zileuton    OR 
Budesonide and all other inhaled corticosteroids (ICS) in all formulation including 
ICS/Long-acting beta-agonist combo  OR 
Montelukast     OR 
Zafirlukast 
AND 
Anosmia 781.1         OR 
Chronic rhinitis 472.0        OR 
Nasal polyp 471        OR 
Prescriptions for any nasal steroid – generic and brand name   OR 
Any procedure code for polypectomy - CPT 31288/30110, P2252/2264  OR 
Any procedure code for nasal endoscopy - CPT31231 
 
Aspirin/NSAID allergy RPDR query: 
 
Personal history of aspirin allergy – V14.6 code OR 
Desensitization – V071.XX code    OR 
Drug allergy NOS – 995.3    OR 
Adverse effect of drug 995.27, 995.29   OR 
Anaphylactic shock NOS 995.0    OR 
Peripheral blood eosinophil count >500/µl  OR 
Eosinophilia 288.3 
 
 
Repository Figure E1. 
 
-- ASTHMA 
select distinct patient_id 
from ( 
select patient_id 
from diagnoses 
where ( 
diagnosis like "*bronchitis and asthma age >17*" or 
diagnosis like "*asthma, unspecified without mention of status asthmaticus*" or 
diagnosis like "*extrinsic asthma without mention of status asthmaticus*" or 
diagnosis like "*asthma, unspecified type, with acute exacerbation*" or 
diagnosis like "*extrinsic asthma with acute exacerbation*" or 
diagnosis like "*chronic obstructive asthma, without mention of status asthmaticus*" 
or 
diagnosis like "*intrinsic asthma without mention of status asthmaticus*" or 
diagnosis like "*extrinsic asthma with status asthmaticus*" or 
diagnosis like "*chronic obstructive asthma with acute exacerbation*" or 
diagnosis like "*asthma, unspecified type, with status asthmaticus*" or 
diagnosis like "*intrinsic asthma, with acute exacerbation*" or 
diagnosis like "*cough variant asthma*" or 
diagnosis like "*intrinsic asthma with status asthmaticus*" or 
diagnosis like "*chronic obstructive asthma, with status asthmaticus*" or 
diagnosis like "*asthma, unspecified*" or 
diagnosis like "*asthma*" or 
diagnosis like "*extrinsic asthma*" or 
diagnosis like "*chronic obstructive asthma*" or 
diagnosis like "*asthma-lmr 29*" or 
diagnosis like "*asthmatic bronchitis-lmr 30*" or 
diagnosis like "*exercise-induced asthma-lmr 1586*" or 
diagnosis like "*asthma, acute exacerbation-lmr 1288*" or 
diagnosis like "*asthma-oncall*" or 
diagnosis like "*asthmatic bronchitis-oncall*" or 
diagnosis like "*exercise induced asthma*" or 
diagnosis like "*exercise induced bronchospasm*" 
) and not ( 
diagnosis like "*bronchitis and asthma age 0-17*" or 
diagnosis like "*family history of asthma*" or 
diagnosis like "*antiasthmatics causing adverse effects in therapeutic use*" or 
diagnosis like "*asthma care model patient-oncall*" 
) 
union 
select patient_id 
from problems 
where ( 
problem = "asthma" or 
problem = "h/o asthma" or 
problem = "allergic asthma" or 
problem = "cough variant asthma" or 
problem = "asthma - resolved" or 
problem = "asthma, acute exacerbation" or 
problem = "asthma/allergic rhinitis" or 
problem = "moderate persistent asthma" or 
problem = "severe persistent asthma" or 
problem = "asthmatic breathing" or 
problem = "extrinsic asthma" or 
problem = "asthma - or eosinophilic bronchitis" or 
problem = "asthma,severe" or 
problem = "chronic obstructive asthma" or 
problem like "*asthma, aspirin sensitive*" or 
problem like "*asthma, frequent steroids*" or 
problem like "*asthma, intubated*" 
)) 
Repository Figure E2. 
 
-- NASAL POLYPS 
select distinct patient_id 
from ( 
select patient_id 
from diagnoses 
where ( 
diagnosis like "*polyp of nasal cavity*" or 
diagnosis like "*nasal polyp*" or 
diagnosis like "*other polyp of sinus*" or 
diagnosis like "*polypoid sinus degeneration*" or 
diagnosis like "*sinus surgery, polyp*" or 
diagnosis like "*sinus polyp*" 
) 
union 
select patient_id 
from problems 
where ( 
problem like "*polyp of nasal cavity*" or 
problem like "*nasal polyp*" or 
problem like "*other polyp of sinus*" or 
problem like "*polypoid sinus degeneration*" or 
problem like "*sinus surgery, polyp*" or 
problem like "*sinus polyp*" 
or (( 
problem like "*sinus*" or 
problem like "*nasal*" or 
problem like "*allergic rhinitis*" 
) and ( 
comments like "*polyp*" 
)) 
) 
) 
Repository Figure E3. 
 
-- NSAID HYPERSENSITIVITY 
select distinct patient_id 
from allergies 
where ( 
allergen like "*aspirin*" or 
allergen = "asa" or 
allergen like "* asa *" or 
allergen like "*+asa *" or 
allergen like "asa *" or 
allergen like "*+asa+*" or 
allergen like "asa-*" or 
allergen like "* asa,*" or 
allergen like "* asa" or 
allergen like "asa,*" or 
allergen like "asa/*" or 
allergen like "*/asa/*" or 
allergen like "* asa,*" or 
allergen like "*,asa,*" or 
allergen like "*nsaid*" or 
allergen like "*ibuprofen*" or 
allergen like "*ibuprophen*" or 
allergen like "*advil*" or 
allergen like "*motrin*" or 
allergen like "*naproxen*" or 
allergen like "*naprosyn*" or 
allergen like "*indomethacin*" or 
allergen like "*ketorolac*" or 
allergen like "*toradol*" or 
allergen like "*salicylic acid*" or 
allergen like "*sulfasalazin*" or 
allergen like "*olsalazin*" or 
allergen like "*sulindac*" or 
allergen like "*etodolac*" or 
allergen like "*flurbiprofen*" or 
allergen like "*ketoprofen*" or 
allergen like "*fenoprofen*" or 
allergen like "*oxaprozin*" or 
allergen like "*mefenamic acid*" or 
allergen like "*meclofenamic acid*" or 
allergen like "*piroxicam*" or 
allergen like "*meloxicam*" or 
allergen like "*diclofenac*" 
) and ( 
reaction like "*bronchospasm*" or 
reaction like "*brochospasm*" or 
reaction like "*bronchoconstriction*" or 
reaction like "*shortness of breath*" or 
reaction like "*sob*" or 
reaction like "*chest tightnes*" or 
reaction like "*asthma*" or 
reaction like "*ashtma*" or 
reaction like "*anaphyla*" or 
reaction like "*amaphyla*" or 
reaction like "*anaphylla*" or 
reaction like "*anaphlaxis*" or 
reaction like "*cough*" or 
reaction like "*wheez*" or 
reaction like "*nasal polyp*" or 
reaction like "*nasla polyp*" or 
reaction like "*nasalpolyp*" or 
reaction like "*asthma, polyp*" or 
reaction like "*nasal stuffines*" or 
reaction like "*nasal congestion*" or 
reaction like "*congestion/nasal*" or 
reaction like "*develops polyps*" or 
reaction like "*rash*" or 
reaction like "*flushing*" or 
reaction like "*sneezing*" or 
reaction like "*resp. react*" or 
reaction like "*respiratory distres*" or 
reaction like "*unable to breath*" or 
reaction like "*difficulty breathing*" or 
reaction like "*difficult to breath*" or 
reaction like "*trouble breathing*" or 
reaction like "*aerd*" or 
reaction like "*sampter*" or 
reaction like "*santer*" or 
reaction like "*samter*" or 
reaction like "*exacerbated respiratory disease*" or 
reaction like "*unknown*" 
) 
Repository Figure E4. 
 
-- KNOWN OR SUSPECTED AERD 
select distinct patient_id 
from ( 
select patient_id, problem as feature 
from problems 
union 
select patient_id, comments as feature 
from problems 
union 
select patient_id, problem_code_description as feature 
from problems 
union 
select patient_id, allergen as feature 
from allergies 
union 
select patient_id, reaction as feature 
from allergies 
) 
where ( 
feature like "*aerd*" or 
feature like "*aspirin-induced asthma*" or 
feature like "*aspirin induced asthma*" or 
feature like "*aspirin-induced respiratory*" or 
feature like "*aspirin induced respiratory*" or 
feature like "*aspirin exacerbated respiratory*" or 
feature like "*aspirin-exacerbated respiratory*" or 
feature like "*exacerbated respiratory disease*" or 
feature like "*aspirin-sensitive asthma*" or 
feature like "*aspirin sensitive asthma*" or 
feature like "*aspirin causes shortness of breath*" or 
feature like "*aspirin causes sob*" or 
feature like "*nsaids, bronchospasm or wheezing*" or 
feature like "*nsaid- breathing difficulty/bronchospasm*" or 
feature like "*samter*" or 
feature like "*sampter*" or 
feature like "*santer*" or 
feature like "*triad asthma*" or 
feature like "*motrin, ibuprofen in high doses over a prolonged 
periodbronchospasm, wheezing*" or 
feature like "*tartrazine (yellow dye#5) - anaphylaxis, asa - asthma*" or 
feature like "*intolerant to asa as it worsens her asthma symptoms*" or 
feature like "*avoids nsaids because of effect on asthma*" or 
feature like "*aspirin cuz asthma attack*" or 
feature like "*asa and nsaids cause hives and sob*" or 
feature like "*asthma*nasal polyp*intoleran*nsaid*" or 
feature like "*asa sensitivity and nasal polyp*" or 
feature like "*asa-sensitivity and nasal polyp*" or 
feature like "*aspirin allergy*nasal*polyp*" or 
feature like "*aspirin-allergy*nasal*polyp*" or 
feature like "*aspirin sensitivity*nasal*polyp*" or 
feature like "*aspirin-sensitivity*nasal*polyp*" or 
feature like "*asa allergy*nasal*polyp*" or 
feature like "*asa-allergy*nasal*polyp*" or 
feature like "*motrine and tylenol gets sob*") 
